

## **MARKSANS PHARMA LIMITED**

Regd. Office: 21st Floor, Lotus Business Park, Off. Link Road, Andheri [West], Mumbai-400053  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2008

(Rs. In lacs)

Sr.	PARTICULARS	Quarter ended		Twelve months ended	
		30th June 08 (UNAUDITED)	30th June 07 (UNAUDITED)	31st March 08 (UNAUDITED)	31st March 07 (AUDITED)
1	Net sales /Income from Operations	7,215.65	4,938.07	26,731.57	24,199.37
2	Other Income	7.51	200.75	642.36	1,051.69
3	Total Expenditure	5,516.70	4,296.67	23,105.39	22,435.32
	-(Increase) /Decrease in Stock in trade	(313.48)	(2.91)	(1,503.42)	(4,088.11)
	-Consumption of Raw Material	4,142.16	2,802.36	18,877.72	20,404.71
	-Staff Cost	768.73	388.29	1,915.79	1,433.17
	-Other Expenditure	919.28	1,108.93	3,815.30	4,685.55
4	Interest	348.10	337.40	1,164.08	1,150.21
5	Depreciation	268.80	201.45	886.68	732.66
6	Profit/(Loss) before Tax	1,089.55	303.30	2,217.78	932.87
7	Provision for Taxation	87.06	35.00	276.82	421.98
8	Net Profit /(Loss)	1,002.49	268.30	1,940.96	510.89
9	Add/Less :Short(Excess) provision/ Prior period expenses/Extra ordinary items	-	-	-	(158.41)
10	Net Profit/(Loss) Before Minority Interest	1,002.49	268.30	1,940.96	669.30
11	Minority Interest	49.38	16.25	45.46	(9.31)
12	Net Profit	953.11	252.05	1,895.50	678.61
13	Paid up Equity Share Capital (Face value Rs. 1 per share)	3,594.06	3,594.06	3,594.06	3,594.06
14	Reserves and Surplus ( Excluding Revaluation Reserve)				
15	Basic and Diluted EPS for the period (Not annualised)	0.27	0.07	0.53	0.19
16	Public Shareholding				
	-Number of Shares	179,622,720	187,765,270	179,622,720	187,765,270
	-Percentage of Share holding	49.98%	52.24%	49.98%	52.24%

Notes:

- The above Consolidated Financial results were reviewed by the Audit Committee and thereafter the Board of Directors have taken it on record at the board meeting held on 31st July 2008.
- The details of investor complaints during the quarter is as under:  
Opening Balance : NIL, Received during the quarter :1, Pending as on 30.06.08 : NIL
- The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd, Marksans Pharma (U.K.) Limited( including its 100% subsidiary Bell, Sons & Co.(Druggiest)Ltd)
- The Acquisition of Bell, Sons & Co (Druggiest) Ltd was completed on 18/01/2008, the Consolidated financial results as at 31/03/2008 includes financials of Bell, Sons & Co from 18/01/2008 to 31/03/2008 only, to that extent the corresponding quarter & year ended figures are not comparable.
- The Consolidated Financial statement are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by institute of Chartered Accountant of India.
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- Statutory Auditors have carried out limited review of the Standalone unaudited financial results and the same are available on the Company's website [www.marksanspharma.com](http://www.marksanspharma.com)

For MARKSANS PHARMA LIMITED

Place: Mumbai

Date: 31st July, 2008

MARK SALDANHA  
Managing Director